ASCO24 Updates: 7+3 vs Decitabine and Venetoclax: Which Treatment is Superior for Elderly Patients?

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most prestigious conferences in oncology. This year, the meeting took place from May 31 to June 4 in Chicago, Illinois. The event gathers oncologists, researchers, healthcare professionals, patients and patient advocates from around the world to discuss the latest advancements in cancer research, treatment, and patient care. Keynote sessions, research presentations, and panel discussions are typically part of the agenda, providing attendees with valuable insights into emerging trends and innovations in oncology.

This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on site. We had the pleasure of interviewing researchers who summarized the highlights of their work.

In this video, Varada Salimath, Internal Medicine Resident at Baylor University Medical Center,  shares insights about their poster on “7+3 versus decitabine + venetoclax: A global, propensity-matched study comparing outcomes for both regimens in AML”. 

Dr. Salimath also had an abstract publication at this year’s meeting titled “Radical prostatectomy versus XRT for early-stage prostate cancer: A retrospective, propensity-matched cohort study of 29,970 patients.”

More videos and content from ASCO 2024 on OncoDaily.